The board of directors of biopharmaceutical company Merck (NYSE:MRK) declared a dividend of USD0.61 per share of the company's common stock for the second quarter of 2020, it disclosed on Tuesday.
Shareholders of record at the close of business as of 16 March 2020 will receive the dividend on 7 April 2020.
Merck said that for more than a century, it has been providing medicines and vaccines for the most challenging diseases.
The company delivers innovative health solutions such as prescription medicines, vaccines, biologic therapies and animal health products. It operates in more than 140 countries.
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025